ExeVir Bio, a spin out of VIB, develops single domain antibody therapies that help patients ward off viral infections. ExeVir aims to become a leader in infectious disease therapy and to prepare the world against pandemics.
XVR011, ExeVir Bio’s lead candidate, has emerged from the labs of highly regarded virologist Pr. Xavier Saelens and biochemist Pr. Nico Callewaert. XVR011, a llama-derived single-domain, Fc fusion, has best-in-class potential, neutralizing SARS-CoV-2 and minimizing the development of lung damage in SARS-COV-2 challenged hamsters. XVR011 has a broad neutralizing potency and is highly conserved across the sarbecovirus subgenus (pan-sarbecoviruses). The heavy-chain only nature of XVR011 brings the additional advantage of being smaller in size with potential for better tissue penetration, low dose, and a rapid, easy, and scalable manufacturing. It also offers the option to develop a more user-friendly sub-cutaneous formulation. The Fc fragment of XVR011 has been silenced for more safety, particularly in more vulnerable sub-populations that are at high risk to develop severe Covid-19 disease